Type 2 diabetes (T2DM), Alzheimer's disease (AD), and insulin resistance are age‐related
conditions and increased prevalence is of public concern. Recent research has provided …

A growing body of evidence links type-2 diabetes (T2D) with dementia and
neurodegenerative diseases such as Alzheimer's disease (AD). AD is the most common …

Targeting the amyloid‐β (Aβ) peptide cascade has been at the heart of therapeutic
developments in Alzheimer's disease (AD) research for more than 25 years, yet no …

There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its
accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes …

In Alzheimer's disease (AD) Aβ accumulates because of imbalance between the production
of Aβ and its removal from the brain. There is increasing evidence that in most sporadic …

Understanding of the role of insulin in the brain has gradually expanded, from initial
conceptions of the brain as insulin-insensitive through identification of a role in regulation of …

In cerebral amyloid angiopathy (CAA), amyloid fibrils deposit in walls of arteries, arterioles
and less frequently in veins and capillaries of the central nervous system, often resulting in …

Insulin‐degrading enzyme (IDE) function goes far beyond its known proteolytic role as a
regulator of insulin levels. IDE has a wide substrate promiscuity, degrading several proteins …

Alzheimer's disease (AD) is the most common form of senile dementia and the fourth highest
cause of disability and death in the elderly. Amyloid-β (Aβ) has been widely implicated in the …

The steady state concentration of the Alzheimer's amyloid-β peptide in the brain represents
a balance between its biosynthesis from the transmembrane amyloid precursor protein …